First Donepezil Transdermal Patch Approved for Alzheimer Disease

Larkin discusses that the first donepezil transdermal patch for treatment of mild, moderate, or severe Alzheimer disease-related dementia has been approved by the FDA. Marketed as Adlarity, the donepezil transdermal delivery system is applied weekly to the back, thigh, or buttocks. The system is designed to continuously deliver medication through the skin, maintaining a constant level needed for effective treatment. Transdermal delivery also may reduce the risk of adverse gastrointestinal effects associated with oral donepezil, according to a statement by manufacturer Corium Inc, as well as ease administration for patients who have trouble swallowing or remembering to take a daily pill.